<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04126551</url>
  </required_header>
  <id_info>
    <org_study_id>1901254125</org_study_id>
    <nct_id>NCT04126551</nct_id>
  </id_info>
  <brief_title>Mitochondrial Methylation in Type 2 Diabetes</brief_title>
  <official_title>Unraveling the Role of Mitochondrial DNA Methylation in Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overarching goal of this proposal is to determine whether DNA methylation of the&#xD;
      mitochondrial DNA impairs mitochondrial function in insulin resistant states such as&#xD;
      overweight/obesity and type 2 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine whether differences in human skeletal muscle DNA methylation patterns in the&#xD;
      mitochondrial and nuclear genome can explain the lower abundance of ETC and OXPHOS mRNA and&#xD;
      protein observed in insulin resistant skeletal muscle of overweight/obese and type 2 diabetic&#xD;
      participants. To determine whether patterns of human skeletal muscle DNA methylation in the&#xD;
      mitochondrial and nuclear genome are predictive of ETC function. We will isolate skeletal&#xD;
      muscle mitochondria from metabolically well-characterized lean insulin sensitive,&#xD;
      overweight/obese insulin resistant nondiabetic and obese insulin resistant type 2 diabetic&#xD;
      volunteers, and functionally evaluate each ETC complex (I - IV) and complex V (ATP synthase).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 23, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mitochondrial DNA methylation</measure>
    <time_frame>3 years</time_frame>
    <description>Mitochondrial DNA methylation and D-loop of mitochondria is altered in insulin resistant states such as overweight/obesity and type 2 diabetes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mitochondrial Function</measure>
    <time_frame>3 years</time_frame>
    <description>The extent of mitochondrial function impairment in insulin resistant participants corresponds to the degree of methylation of the mitochondrial genome and D-loop</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Overweight</condition>
  <condition>Obesity</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Lean, healthy control</arm_group_label>
    <description>Lean, healthy control subjects. Volunteers will be matched for sex and age 21-55 years old. Ethnicities studied will be self-reported. We will attempt to match on race/ethnicities with equal numbers of non-Hispanic/Latinos and Hispanics/Latinos.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Overweight/obese nondiabetic</arm_group_label>
    <description>Overweight/Obese nondiabetic subjects. Overweight and obesity will be defined using the standard body mass index cutoffs. Volunteers will be matched for sex and age 21-55 years old. Ethnicities studied will be self-reported. We will attempt to match on race/ethnicities with equal numbers of non-Hispanic/Latinos and Hispanics/Latinos.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type 2 diabetes</arm_group_label>
    <description>Participants with type 2 diabetes will be diagnosed accordingly to ADA criteria. Volunteers will be matched for sex and age 21-55 years old. Ethnicities studied will be self-reported. We will attempt to match on race/ethnicities with equal numbers of non-Hispanic/Latinos and Hispanics/Latinos.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Methylation status</intervention_name>
    <description>Participants will be recruited, and muscle biopsies will be obtained for methylation analyses and measuring mitochondrial function</description>
    <arm_group_label>Lean, healthy control</arm_group_label>
    <arm_group_label>Overweight/obese nondiabetic</arm_group_label>
    <arm_group_label>Type 2 diabetes</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA will be extracted from vastus lateralis skeletal muscle biopsies and blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Three groups of volunteers will be studied: 1) lean, healthy volunteers, 2)&#xD;
        overweight/obese volunteers without type 2 diabetes, and 3) volunteers with type 2 diabetes&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects must be 21-55 years old&#xD;
&#xD;
          2. Body Mass Index:&#xD;
&#xD;
             Lean, healthy BMI ≤25; Overweight,non-diabetic BMI 25-29.9; Obese, non-diabetic BMI&#xD;
             30-50; Type 2 Diabetes (per the American Diabetes Association criteria)&#xD;
&#xD;
          3. Subjects must be able to communicate meaningfully with the investigator and must be&#xD;
             legally competent to provide written informed consent.&#xD;
&#xD;
          4. Female subjects must be non-lactating and will be eligible only if they have a&#xD;
             negative pregnancy test throughout the study period, and must agree to use acceptable&#xD;
             birth control (hormonal contraceptives, barrier methods, have an intrauterine device,&#xD;
             or surgical sterilization)&#xD;
&#xD;
          5. Subjects must have the following laboratory values:&#xD;
&#xD;
               -  Hematocrit ≥ 35 vol%&#xD;
&#xD;
               -  Serum creatinine ≤ 1.6 mg/dl&#xD;
&#xD;
               -  AST (SGOT) &lt; 2 times upper limit of normal&#xD;
&#xD;
               -  ALT (SGPT) &lt; 2 times upper limit of normal&#xD;
&#xD;
               -  Alkaline phosphatase &lt; 2 times upper limit of normal&#xD;
&#xD;
               -  Triglycerides &lt; 150 mg/dl for nondiabetics&#xD;
&#xD;
               -  Triglycerides &lt;300 for diabetics&#xD;
&#xD;
               -  INR ≤ 1.3&#xD;
&#xD;
               -  HbA1c ≤ 10&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects must not be receiving any of the following medications: thiazide or&#xD;
             furosemide diuretics, beta-blockers, or other chronic medications with known adverse&#xD;
             effects on glucose tolerance levels unless the patient has been on a stable dose of&#xD;
             such agents for the past three months before entry into the study. Subjects must not&#xD;
             be taking estrogens or other hormonal replacement therapy unless the subject has been&#xD;
             on these agents on a stable dose for the prior three months. Subjects taking systemic&#xD;
             glucocorticoids are excluded. Patients with type 2 diabetes will be excluded if they&#xD;
             are taking thiazolidinediones.&#xD;
&#xD;
          2. Subjects receiving Gemfibrozil must not also be receiving a statin.&#xD;
&#xD;
          3. Subjects with a history of clinically significant heart disease (New York Heart&#xD;
             Classification greater than grade II; more than non-specific ST-T wave changes on the&#xD;
             EKG), peripheral vascular disease (history of claudication), or pulmonary disease&#xD;
             (dyspnea on exertion of one flight or less; abnormal breath sounds on auscultation)&#xD;
             will not be studied.&#xD;
&#xD;
          4. Recent systemic or pulmonary embolus, untreated high-risk proliferative retinopathy,&#xD;
             recent retinal hemorrhage, uncontrolled hypertension, systolic BP&gt;160, diastolic&#xD;
             BP&gt;95, autonomic neuropathy, resting heart rate &gt;100, electrolyte abnormalities.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dawn K Coletta, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dawn K Coletta, PhD</last_name>
    <phone>520-626-9316</phone>
    <email>dcoletta@email.arizona.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Gordon</last_name>
    <phone>520-626-5472</phone>
    <email>mgordon@email.arizona.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical and Translational Research Center (CaTS)</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Gordon</last_name>
      <phone>520-626-5472</phone>
      <email>mgordon@email.arizona.edu</email>
    </contact>
    <contact_backup>
      <last_name>Alma Leon</last_name>
      <phone>520-626-7006</phone>
      <email>almadleon@email.arizona.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Dawn K Coletta, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 11, 2019</study_first_submitted>
  <study_first_submitted_qc>October 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2019</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Arizona</investigator_affiliation>
    <investigator_full_name>Dawn K Coletta</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

